Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen Closes $1.6B Digene Acquisition, Opens Hong Kong Subsidiary

NEW YORK (GenomeWeb News) - Qiagen said yesterday it has closed its acquisition of Digene through a tender offer and merger valued at around $1.6 billion, under which Digene will become a wholly owned subsidiary of Qiagen North American Holdings.
Qiagen announced its intention to purchase the firm in early June.
Digene's central offering is a diagnostic test for human papillomavirus. One of its tests has been approved by the US Food and Drug Administration and has received CE-mark clearance by European regulators.
In June, Qiagen CEO Peer Schatz said the acquisition of Digene's molecular diagnostics assets would provide the firm "with many ways to drive top-line and bottom-line growth, such as access to new channels with existing and new products and combined technology, resources and infrastructure to provide greater operating strengths."
Under the terms of the deal, Qiagen shareholders agreed to pay $61.25 or 3.545 shares of Qiagen stock for each share of Digene stock. Qiagen today said that 94 percent of Digene shares were tendered and that 90 percent of the shares tendered opted to receive Qiagen stock.
Advisors for the transaction were Goldman Sachs for Qiagen and JP Morgan for Digene.
In a separate announcement today, Qiagen said that it has opened a new subsidiary in Hong Kong, which will serve as the hub for further expansion in the region.
Frauke Ehlert, general manager of Qiagen China and Hong Kong, said in a statement, "Hong Kong is a focal point for science, healthcare and the fast-developing market for biomedical research."
Qiagen has 12 offices and approximately 300 employees throughout Asia. According to the firm, Asian sales contribute 15 percent to Qiagen's overall revenues.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.